Report Detail

Request for Sample of this report

Medical Industry Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

  • RnM3977164
    • |
  • 25 May, 2020
    • |
  • Global
    • |
  • 117 Pages
    • |
  • QYResearch
    • |
  • Medical Industry

Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.
Market Analysis and Insights: Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
Prior to COVID-19, the market for Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market.
Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Scope and Segment
The global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026.
This report also analyzes the impact of Coronavirus COVID-19 on the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics industry.
By the type, the market is primarily split into
Therapeutics
Diagnostics
By the application, this report covers the following segments
Hospital
Clinic
Competitive Landscape:
The Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics key manufacturers in this market include:
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals


1 Market Overview of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

  • 1.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Overview
    • 1.1.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Scope
    • 1.1.2 Market Status and Outlook
  • 1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Overview by Region 2015 VS 2020 VS 2026
  • 1.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2015-2026)
  • 1.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Region (2015-2020)
  • 1.5 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Region (2021-2026)
  • 1.6 Covid-19 Impact on Key Regions, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2015-2026)
    • 1.6.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2015-2026)
    • 1.6.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2015-2026)
    • 1.6.3 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2015-2026)
    • 1.6.4 Rest of Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2015-2026)
    • 1.6.5 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2015-2026)
    • 1.6.6 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2015-2026)
  • 1.7 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.7.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.7.2 Covid-19 Impact: Commodity Prices Indices
    • 1.7.3 Covid-19 Impact: Global Major Government Policy

2 Covid-19 Impact on Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Overview by Type

  • 2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type: 2015 VS 2020 VS 2026
  • 2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Type (2015-2020)
  • 2.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Type (2021-2026)
  • 2.4 Therapeutics
  • 2.5 Diagnostics

3 Covid-19 Impact on Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Overview by Application

  • 3.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application: 2015 VS 2020 VS 2026
  • 3.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Application (2015-2020)
  • 3.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Application (2021-2026)
  • 3.4 Hospital
  • 3.5 Clinic

4 Covid-19 Impact on Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Competition Analysis by Players

  • 4.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (Million US$) by Players (2015-2020)
  • 4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2019)
  • 4.3 Date of Key Manufacturers Enter into Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
  • 4.4 Global Top Players Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Headquarters and Area Served
  • 4.5 Key Players Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Solution and Service
  • 4.6 Competitive Status
    • 4.6.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Rate
    • 4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles and Key Data

  • 5.1 Siemens Healthcare
    • 5.1.1 Siemens Healthcare Profile
    • 5.1.2 Siemens Healthcare Main Business and Company’s Total Revenue
    • 5.1.3 Siemens Healthcare Products, Services and Solutions
    • 5.1.4 Siemens Healthcare Revenue (US$ Million) (2015-2020)
    • 5.1.5 Siemens Healthcare Recent Development and Reaction to Covid-19
  • 5.2 Celerion
    • 5.2.1 Celerion Profile
    • 5.2.2 Celerion Main Business and Company’s Total Revenue
    • 5.2.3 Celerion Products, Services and Solutions
    • 5.2.4 Celerion Revenue (US$ Million) (2015-2020)
    • 5.2.5 Celerion Recent Development and Reaction to Covid-19
  • 5.3 ZyVersa Therapeutics, Inc.
    • 5.5.1 ZyVersa Therapeutics, Inc. Profile
    • 5.3.2 ZyVersa Therapeutics, Inc. Main Business and Company’s Total Revenue
    • 5.3.3 ZyVersa Therapeutics, Inc. Products, Services and Solutions
    • 5.3.4 ZyVersa Therapeutics, Inc. Revenue (US$ Million) (2015-2020)
    • 5.3.5 Cisbio Recent Development and Reaction to Covid-19
  • 5.4 Cisbio
    • 5.4.1 Cisbio Profile
    • 5.4.2 Cisbio Main Business and Company’s Total Revenue
    • 5.4.3 Cisbio Products, Services and Solutions
    • 5.4.4 Cisbio Revenue (US$ Million) (2015-2020)
    • 5.4.5 Cisbio Recent Development and Reaction to Covid-19
  • 5.5 Regeneron Pharmaceuticals, Inc.
    • 5.5.1 Regeneron Pharmaceuticals, Inc. Profile
    • 5.5.2 Regeneron Pharmaceuticals, Inc. Main Business and Company’s Total Revenue
    • 5.5.3 Regeneron Pharmaceuticals, Inc. Products, Services and Solutions
    • 5.5.4 Regeneron Pharmaceuticals, Inc. Revenue (US$ Million) (2015-2020)
    • 5.5.5 Regeneron Pharmaceuticals, Inc. Recent Development and Reaction to Covid-19
  • 5.6 BioPredictive
    • 5.6.1 BioPredictive Profile
    • 5.6.2 BioPredictive Main Business and Company’s Total Revenue
    • 5.6.3 BioPredictive Products, Services and Solutions
    • 5.6.4 BioPredictive Revenue (US$ Million) (2015-2020)
    • 5.6.5 BioPredictive Recent Development and Reaction to Covid-19
  • 5.7 Echosens
    • 5.7.1 Echosens Profile
    • 5.7.2 Echosens Main Business and Company’s Total Revenue
    • 5.7.3 Echosens Products, Services and Solutions
    • 5.7.4 Echosens Revenue (US$ Million) (2015-2020)
    • 5.7.5 Echosens Recent Development and Reaction to Covid-19
  • 5.8 Genfit
    • 5.8.1 Genfit Profile
    • 5.8.2 Genfit Main Business and Company’s Total Revenue
    • 5.8.3 Genfit Products, Services and Solutions
    • 5.8.4 Genfit Revenue (US$ Million) (2015-2020)
    • 5.8.5 Genfit Recent Development and Reaction to Covid-19
  • 5.9 Enterome
    • 5.9.1 Enterome Profile
    • 5.9.2 Enterome Main Business and Company’s Total Revenue
    • 5.9.3 Enterome Products, Services and Solutions
    • 5.9.4 Enterome Revenue (US$ Million) (2015-2020)
    • 5.9.5 Enterome Recent Development and Reaction to Covid-19
  • 5.10 NGM Biopharmaceuticals
    • 5.10.1 NGM Biopharmaceuticals Profile
    • 5.10.2 NGM Biopharmaceuticals Main Business and Company’s Total Revenue
    • 5.10.3 NGM Biopharmaceuticals Products, Services and Solutions
    • 5.10.4 NGM Biopharmaceuticals Revenue (US$ Million) (2015-2020)
    • 5.10.5 NGM Biopharmaceuticals Recent Development and Reaction to Covid-19

6 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Players and by Application

  • 6.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size and Market Share by Players (2015-2020)
  • 6.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2015-2020)

7 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Players and by Application

  • 7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size and Market Share by Players (2015-2020)
  • 7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2015-2020)

8 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Players and by Application

  • 8.1 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size and Market Share by Players (2015-2020)
  • 8.2 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2015-2020)

9 Rest of Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Players and by Application

  • 9.1 Rest of Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size and Market Share by Players (2015-2020)
  • 9.2 Rest of Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2015-2020)

10 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Players and by Application

  • 10.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size and Market Share by Players (2015-2020)
  • 10.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2015-2020)

11 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Players and by Application

  • 11.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size and Market Share by Players (2015-2020)
  • 11.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2015-2020)

12 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Dynamics

  • 12.1 Covid-19 Impact: Industry Trends
  • 12.2 Covid-19 Impact: Market Drivers
  • 12.3 Covid-19 Impact: Market Challenges
  • 12.4 Porter’s Five Forces Analysis

13 Research Finding /Conclusion

    14 Methodology and Data Source

    • 14.1 Methodology/Research Approach
      • 14.1.1 Research Programs/Design
      • 14.1.2 Market Size Estimation
      • 14.1.3 Market Breakdown and Data Triangulation
    • 14.2 Data Source
      • 14.2.1 Secondary Sources
      • 14.2.2 Primary Sources
    • 14.3 Disclaimer

    Summary:
    Get latest Market Research Reports on Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics. Industry analysis & Market Report on Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics is a syndicated market report, published as Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application. It is complete Research Study and Industry Analysis of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,500.00
    		$7,000.00
    		2,817.50
    		5,635.00
    		3,384.50
    		6,769.00
    		530,565.00
    		1,061,130.00
    		306,880.00
    		613,760.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo